SecBot SecBot
Biotech Drug Report Generated Nov 10, 2026

varegacestat

IMNM·Immunome Inc.
BULLISH
Drug Impact Rating8/10
Trial phase
Filed/PDUFA
Time to market
FDA PDUFA target action date is April 28, 2027. EMA review is also underway following MAA validation in October 2026. If approved, varegacestat could launch in the US in the second half of 2027.
Why 8/10
The next hard, dated catalyst is the FDA PDUFA target action date of April 28, 2027, roughly 5.5 months away. Varegacestat is Immunome's lead asset and drives most of the company's valuation, making this a make-or-break binary event for a single-asset-focused biotech, though the company also has early-stage pipeline programs and $461.6M in cash.
Actionable Insight BULLISH

The single most important catalyst is the FDA PDUFA decision on April 28, 2027. Approval would make varegacestat the second FDA-approved therapy for desmoid tumors and unlock a meaningful commercial opportunity, while a Complete Response Letter would severely pressure the stock given the company's pre-revenue status and reliance on this asset. Watch for EMA review progress and Q3 earnings on November 16 for pipeline updates and cash runway details.

Price Chart

Loading chart...

Executive Summary

Varegacestat (AL102) is Immunome's lead drug candidate, an oral gamma secretase inhibitor for desmoid tumors, a rare soft-tissue condition. The Phase 3 RINGSIDE trial produced exceptionally strong efficacy data (84% risk reduction, HR=0.16), and the NDA is under FDA review with a PDUFA date of April 28, 2027. The EMA has also validated the MAA. Immunome recently bought out all future milestone and royalty obligations to Bristol-Myers Squibb for $20M cash plus stock, giving it full economic ownership. The stock trades at $19.36 with a consensus analyst price target of $35.33 (82.5% implied upside), though the company is pre-revenue and burning cash ($85.8M net loss in Q3 2026).

How It Works

Varegacestat is an oral, once-daily pill that blocks gamma secretase, an enzyme involved in cell signaling pathways that drive the growth of desmoid tumors. By inhibiting this enzyme, the drug aims to slow or stop tumor progression.

Trial Status

The global pivotal Phase 3 RINGSIDE trial in adults with progressing desmoid tumors met its primary endpoint of improving progression-free survival (HR=0.16, p<0.0001, an 84% reduction in risk of progression or death) and all key secondary endpoints. Detailed results were presented at ASCO 2026 and additional analyses at ESMO 2026. A New Drug Application (NDA) was submitted to the FDA in April 2026, accepted in July 2026, and a Marketing Authorization Application (MAA) was validated by the EMA in October 2026.

The Two-Sided Case

▲ Bull Case5
Phase 3 RINGSIDE data were exceptionally strong: varegacestat reduced the risk of progression or death by 84% vs placebo (HR=0.16, p<0.0001) and met all key secondary endpoints, setting a high bar for approval.
The NDA was accepted by the FDA with a PDUFA date of April 28, 2027, and the EMA validated the MAA in October 2026, indicating dual-track regulatory progress.
Immunome bought out all future milestone and royalty obligations to Bristol-Myers Squibb for $20M cash plus 4.43M shares, giving it full economic ownership of varegacestat with no future payment overhang.
Analyst consensus is overwhelmingly bullish: 21 of 23 analysts rate it Buy or Strong Buy, with a mean price target of $35.33 (82.5% upside from $19.36).
Cash position of $461.6M provides runway into 2028, reducing near-term financing risk.
▼ Bear Case5
Varegacestat would enter a market with an existing approved therapy: SpringWorks Therapeutics' Ogsiveo (nirogacestat), which generated $172M in revenue in 2024 and is already established.
Parabilis Medicines' zolucatetide (FOG-001), a beta-catenin inhibitor with a different mechanism, is in Phase 1/2 development for desmoid tumors and has orphan drug designation, representing future competition.
Immunome is pre-revenue with accelerating cash burn: R&D expenses rose 41% YoY to $69.5M, and net loss widened to $85.8M in Q3 2026 from $57.5M a year earlier.
Insider selling: the Chief Scientific Officer sold $334k in shares in September 2026 and a director sold $301k in August 2026, both under 10b5-1 plans.
Several large institutional holders trimmed or exited in Q2 2026, including Jefferies (exit), T. Rowe Price (-38%), and Marshall Wace (-66%).

Upcoming Catalysts

  • FDA PDUFA decision on varegacestat NDA: April 28, 2027
  • EMA review of MAA for varegacestat (ongoing, no decision date set)
  • Q3 2026 earnings report: November 16, 2026
  • ASH 2026 data for pipeline asset IM-1021: December 14, 2026

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Immunome Inc. 8-K IMNM ·Originating report

Sources · 12

Hover a chip for the title
1 nasdaq.com2 businesswire.com3 streetinsider.com4 streetinsider.com5 nasdaq.com6 morningstar.com7 empr.com8 cancernetwork.com9 seekingalpha.com10 sec.gov11 sec.gov12 cancernetwork.com